(Q37095697)

18 August 2017

1 reference

title

Abacavir hypersensitivity reaction: an update (English)

1 reference

18 August 2017

1 reference

Christine A Hughes

1

1 reference

18 August 2017

Michelle M Foisy

2

1 reference

18 August 2017

Norman Dewhurst

3

1 reference

18 August 2017

Niamh Higgins

4

1 reference

18 August 2017

Linda Robinson

5

1 reference

18 August 2017

Deborah V Kelly

6

1 reference

18 August 2017

Kelly E Lechelt

7

1 reference

18 August 2017

language of work or name

English

0 references

publication date

26 February 2008

1 reference

Annals of Pharmacotherapy

18 August 2017

published in

1 reference

18 August 2017

volume

42

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

387-396

1 reference

Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase

18 August 2017

cites work

1 reference

Abacavir plus lamivudine: a review of their combined use in the management of HIV infection

21 January 2018

1 reference

Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection

21 January 2018

1 reference

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

The abacavir hypersensitivity reaction: a review

21 January 2018

1 reference

Abacavir hypersensitivity reaction

21 January 2018

1 reference

Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient

21 January 2018

1 reference

Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate

21 January 2018

1 reference

Disseminated intravascular coagulation as a manifestation of abacavir hypersensitivity reaction

21 January 2018

1 reference

Agranulocytosis and fever seven weeks after starting abacavir

21 January 2018

1 reference

Acute respiratory manifestations of the abacavir hypersensitivity reaction

21 January 2018

1 reference

Sweet's syndrome following abacavir therapy

21 January 2018

1 reference

Stevens-Johnson syndrome associated with abacavir therapy

21 January 2018

1 reference

Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity

21 January 2018

1 reference

Unusual clinical presentation of hypersensitivity reaction to abacavir

21 January 2018

1 reference

The abacavir hypersensitivity reaction and interruptions in therapy

21 January 2018

1 reference

Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient

21 January 2018

1 reference

Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug

21 January 2018

1 reference

Risk factor analysis of hypersensitivity reactions to abacavir

21 January 2018

1 reference

Epidemiological risk factors for hypersensitivity reactions to abacavir*

21 January 2018

1 reference

Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir

21 January 2018

1 reference

Once-daily abacavir in place of twice-daily administration

21 January 2018

1 reference

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

21 January 2018

1 reference

Abacavir hypersensitivity reaction in primary HIV infection

21 January 2018

1 reference

Hypersensitivity related to abacavir in two members of a family

21 January 2018

1 reference

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

21 January 2018

1 reference

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction

21 January 2018

1 reference

Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir

21 January 2018

1 reference

Clinical and immunogenetic correlates of abacavir hypersensitivity

21 January 2018

1 reference

Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.

21 January 2018

1 reference

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

21 January 2018

1 reference

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

Bringing genomics to the bedside: a cost-effective pharmacogenomic test?

21 January 2018

1 reference

Anaphylaxis after rechallenge with abacavir

21 January 2018

1 reference

Abacavir Hypersensitivity Reaction after Switching from the Twice-Daily to the Once-Daily Formulation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1K522

1 reference

18 August 2017

1 reference